Main Article Content

Sufyan Muhammed Al-Dulaimi
Huda Rafaa Al-alwani
Bassam Francis Matti


Acute myeloid leukemia, Hematological parameters, WBC count, Platelets count, Hemoglobin levels, Chemotherapy


Objective: To assess the alterations in hematological indicators of Iraqi patients with acute myeloid leukemia before and post-chemotherapy.
Material and method: This is a case-control study of newly diagnosed acute myeloid leukemia (AML) cases in the Iraqi population diagnosed between February 2022 and November 2022 at the Iraqi Center for Hematology in the Medical City in Baghdad teaching hospital. Peripheral blood samples were taken from all participants. An automated hematology analyzer determined WBC, HB, and Platelet count. Blast cell% in the peripheral blood was estimated on Giemsa-stained blood smears. The blood film examination was done for WBC differential count. Mean and standard deviation was used for quantitative, while frequency and percentages were used for qualitative data.
Results: A total of 40 patients were newly diagnosed with AML, the majority of the patients were male, and the most common subtype of AML was Acute myeloblastic leukemia-M2. Most of the patients are between 51-61 (35%) years old. Most patients had leukocytosis, anemia, and thrombocytopenia, and blast cells were present in the peripheral blood of 90% of the AML patients. The results also showed a significant increase in WBC count and a significant decrease in platelet count and hemoglobin concentrations in AML patients compared to healthy controls. A significant decrease was observed in most of the hematological parameters after Chemotherapy.
Conclusion: In this study, all patients with AML have abnormal levels of all hematological parameters. The patients who received Chemotherapy show different levels of these parameters, such as WBC, HB, Platelet count and Blast cells. It is obvious that AML has a strong impact on the hematological parameters.

Abstract 119 | pdf Downloads 185


1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, The Journal of the American Society of Hematology. 2016;127(20):2391-405.
2. Ashkan Emadi JYL. Acute Myeloid Leukemia (AML) MSDmanuals: The American Cancer Society; 2022 [Available from:
3. Rathee R, Vashist M, Kumar A, Singh S. Incidence of acute and chronic forms of leukemia in Haryana. Int J Pharm Pharm Sci. 2014;6(02):323-5.
4. Estey EH. Acute myeloid leukemia: 2019 update on risk‐stratification and management. American Journal of Hematology. 2018;93(10):1267-91.
5. Arber DA. The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. Semin Hematol. 2019;56(2):90-5.
6. Betz BL, Hess JL. Acute myeloid leukemia diagnosis in the 21st century. Archives of pathology & laboratory medicine. 2010;134(10):1427-33.
7. Al-Seraihy A, Al-Mansour, M., Al-Zahrani, M., Al-Dosari, M., & Al-Qahtani, A. Acute myeloid leukemia: current treatment options and future directions. International Journal of Hematology-Oncology and Stem Cell Research. 2015:70-6.
8. Naghmi A, Khalid H. Acute myeloid leukemia amongst adults. 2013.
9. Chang F, Shamsi TS, Waryah A. Clinical and hematological profile of acute myeloid leukemia (AML) patients of Sindh. Journal of Hematology & Thromboembolic Diseases. 2016.
10. Hossain MS, Iqbal MS, Khan MA, Rabbani MG, Khatun H, Munira S, et al. Diagnosed hematological malignancies in Bangladesh-a retrospective analysis of over 5000 cases from 10 specialized hospitals. BMC cancer. 2014;14:1-7.
11. Barrington‐Trimis JL, Cockburn M, Metayer C, Gauderman WJ, Wiemels J, McKean‐Cowdin R. Trends in childhood leukemia incidence over two
decades from 1992 to 2013. International journal of cancer. 2017;140(5):1000-8.
12. Ben-Batalla I, Vargas-Delgado ME, Meier L, Loges S, editors. Sexual dimorphism in solid and hematological malignancies. Seminars in Immunopathology; 2019: Springer.
13. Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer. 2013;119(23):4162-9.
14. Kim H-I, Lim H, Moon A. Sex differences in cancer: epidemiology, genetics and therapy. Biomolecules & therapeutics. 2018;26(4):335.
15. Alwan AF, Zedan ZJ, Salman OS. Acute myeloid leukemia: clinical features and follow-up of 115 Iraqi patients admitted to Baghdad Teaching Hospital. Tikrit Med J. 2009;15(1):1-8.
16. Abdulateef S, Almothaffar A, Al-khafaji KR. Molecular study of FLT3-ITD mutation in Iraqi adult acute myeloid leukemia patients; Its correlation with clinicopathological parameters. Pathol Lab Med. 2017;1:79-82.
17. Mahmood EF, Ahmed AA. Evaluation of interleukin-35 and interleukin-10 in adult acute myeloid leukemia patients before and after induction chemotherapy. Iraqi Journal of Hematology. 2020;9(2):82.
18. Nasreldin E, Safwat D, Hamed H, Mohamed S. T-regulatory and T-helper type17 cells associated cytokines (IL-35, IL-17) as potential diagnostic and prognostic biomarkers in Egyptian acute myeloid leukemia patients. J Clin Cell Immunol. 2016;7(478):2.
19. Vakiti A, Mewawalla P. Acute Myeloid Leukemia. StatPearls [Internet]. 2020.
20. Ferrara F, Schiffer CA. Acute myeloid leukemia in adults. The Lancet. 2013;381(9865):484-95.
21. Konieczny J, Arranz L. Updates on old and weary haematopoiesis. International journal of molecular sciences. 2018;19(9):2567.
22. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Acute Leukemias. 2008:47-56.
23. Abuhelwa Z, Al Shaer Q, Taha S, Ayoub K, Amer R. Characteristics of de novo acute myeloid leukemia patients in Palestine: experience of An-Najah National University Hospital. Asian Pacific Journal of cancer prevention: APJCP. 2017;18(9):2459.
24. Al-Husseiny A. Acute myeloid leukemia in adolescent and adult Iraqi patients clinical and hematological study. Diala J. 2008;29:1-11.
25. Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak ML. Prognostic impact of acute myeloid leukemia classification: the importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. American Journal of clinical pathology. 2003;119(5):672-80.
26. Moussavi F, Hosseini S, Saket S, Derakhshanfar H. The First CBC in Diagnosis of childhood acute lymphoblastic leukemia. International Journal of Medical Investigation. 2014;3(1):0-.
27. Lyengar V, Shimanovsky A. Leukemia. StatPearls. 2021.
28. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology 2013, the American Society of Hematology Education Program Book. 2013;2013(1):220-6.
29. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, The Journal of the American Society of Hematology. 2010;115(3):453-74.
30. Naeem R, Naeem S, Sharif A, Rafique H, Naveed A. Acute Myeloid Leukemia: Demographic Features And Frequency Of Various Subtypes In Adult Age GROUP. The Professional Medical Journal. 2017;24(09):1302-5.
31. Masetti R, Vendemini F, Zama D, Biagi C, Pession A, Locatelli F. Acute myeloid leukemia in infants: biology and treatment. Frontiers in pediatrics. 2015;3:37.
32. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. New England Journal of Medicine. 1962;266(18):905-9.
33. Sultan S, Zaheer HA, Irfan SM, Ashar S. Demographic and clinical characteristics of adult acute Myeloid Leukemia-tertiary care experience. Asian Pacific Journal of Cancer Prevention. 2016;17(1):357-60.
34. Preethi C. Clinico-hematological study of acute myeloid leukemias. Journal of Clinical and Diagnostic Research: JCDR. 2014;8(4):FC14.